# A Phase 1 Study to Assess HM15275 in Healthy and Obese Subjects.

> **NCT06481098** · PHASE1 · COMPLETED · sponsor: **Hanmi Pharmaceutical Company Limited** · enrollment: 74 (actual)

## Conditions studied

- Obesity

## Interventions

- **DRUG:** HM15275
- **DRUG:** Placebo of HM15275

## Key facts

- **NCT ID:** NCT06481098
- **Lead sponsor:** Hanmi Pharmaceutical Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-05-28
- **Primary completion:** 2025-05-02
- **Final completion:** 2025-05-02
- **Target enrollment:** 74 (ACTUAL)
- **Last updated:** 2025-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06481098

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06481098, "A Phase 1 Study to Assess HM15275 in Healthy and Obese Subjects.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06481098. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*